Niraparib Tosylate
Brand name: Zejula
Rank #323 of 500 drugs by total cost
$33.7M
Total Cost
2,206
Total Claims
$33.7M
Total Cost
125
Prescribers
$15K
Cost per Claim
0
Beneficiaries
2,220
30-Day Fills
$270K
Avg Cost/Provider
18
Avg Claims/Provider
About Niraparib Tosylate
Niraparib Tosylate (sold as Zejula) was prescribed 2,206 times by 125 Medicare Part D providers in 2023, costing the program $33.7M. At $15K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 320 | Tolvaptan (Jynarque) | $34.4M | 2,760 |
| 321 | Dalfampridine (Dalfampridine Er) | $34.1M | 40,425 |
| 322 | Olmesartan Medoxomil (Olmesartan Medoxomil) | $33.8M | 1,102,412 |
| 323 | Niraparib Tosylate (Zejula) | $33.7M | 2,206 |
| 324 | Tapentadol Hcl (Nucynta) | $33.6M | 29,886 |
| 325 | Dorzolamide Hcl/Timolol Maleat (Dorzolamide-Timolol) | $33.5M | 1,096,480 |
| 326 | Morphine Sulfate (Morphine Sulfate Er) | $33.2M | 1,023,056 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology